Edward Brian Garon MD
Assistant Professor, Medicine, UCLA School of Medicine
Join to View Full Profile
2020 Santa Monica Blvd., 6th FloorSanta Monica, CA 90404
Phone+1 310-829-5471
Fax+1 310-829-5471
Dr. Garon is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of ChicagoResidency, Internal Medicine, 1999 - 2002
WashU MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2003 - 2028
IL State Medical License 1999 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Oct 28
- Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2009 Jan 01
- Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 01
Publications & Presentations
PubMed
- Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.Mark A Socinski, Rolf Stahel, Dae Ho Lee, Federico Cappuzzo, Makoto Nishio
JAMA Oncology. 2026-06-01 - Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test.Weihua Zeng, Chun-Chi Liu, Shuo Li, Yonggang Zhou, Mary L Stackpole
Proceedings of the National Academy of Sciences of the United States of America. 2026-04-14 - Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer.Sara Sakowitz, Haley I Tupper, Lawrence N Benjamin, Scott Oh, Tao He
Chest. 2026-04-01
Journal Articles
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung CancerEdward B Garon, Maeve Waldron-Lynch, The New England Journal of Medicine
Lectures
- Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.2019 ASCO Annual Meeting - 6/1/2019
- Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Controversies, Difficult Questions Arise in NSCLC Amid New DataFebruary 2024
Press Mentions
ESMO: 10-Year Survival Data for Lung Cancer Immunotherapy, New PSMA-Targeted Therapy for Recurrent Prostate Cancer, Promising Results in Metastatic Colorectal and Urothelial CancersOctober 20th, 2025- Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS CongressApril 26th, 2025
- Dr. Garon on Considerations Regarding the Use of Perioperative Immunotherapy in Lung CancerJuly 4th, 2024
Grant Support
- HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapyUNIVERSITY OF CALIFORNIA LOS ANGELES2023–2028
- HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapyUNIVERSITY OF CALIFORNIA LOS ANGELES2023–2028
- Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.UNIVERSITY OF CALIFORNIA LOS ANGELES2023–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
